Chester County News and Community Website
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for Friedreich’s ataxia (FA), marking an important step in …
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced encouraging initial results from its ongoing open-label extension (OLE) study evaluating long-term daily injections of nomlabofusp for Friedreich’s ataxia …
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) recently presented encouraging data from its studies on nomlabofusp at the International Congress for Ataxia Research in London. The data, derived …
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has released its financial results for the third quarter of 2024, alongside updates on its nomlabofusp program aimed at treating Friedreich’s …
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and Phase 2 studies at the International Congress for Ataxia Research …
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is gearing up for significant investor engagement this September. The company’s management will meet with investors at the Wells Fargo Healthcare …
Larimar Therapeutics Engages with Investors at Key Conferences Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced its second-quarter 2024 financial results and significant progress in its nomlabofusp development program.
Larimar Therapeutics Reports Q2 2024 Financial Results and Milestones Read More BALA CYNWYD, PA — Larimar Therapeutics announced that its novel therapy nomlabofusp has been chosen to participate in the FDA’s Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot …
Larimar Therapeutics’ Nomlabofusp Selected for FDA’s START Program Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced this week that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its nomlabofusp (CTI-1601) …
Larimar Therapeutics Advances Friedreich’s Ataxia Treatment After FDA Lifts Hold Read More BALA CYNWYD, PA — Larimar Therapeutics (Nasdaq: LRMR) recently unveiled its Q1 2024 operational and financial results. The biopharmaceutical company is making remarkable progress in the clinical program of their …
Larimar Therapeutics’ Promising Q1 2024 Results Show Potential Treatment for Friedreich’s Ataxia Read More